Welcome to our dedicated page for Avita Medical news (Ticker: RCEL), a resource for investors and traders seeking the latest updates and insights on Avita Medical stock.
News and updates on AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) focus on its role as a therapeutic acute wound care company centered on the RECELL System and related wound care technologies. Company news frequently highlights developments in thermal burn and trauma treatment, clinical evidence for its products, and regulatory milestones in key markets.
Investors following RCEL news can expect coverage of financial results, revenue updates, and capital structure actions such as credit agreements and equity placements, as disclosed in Form 8-K filings and press releases. AVITA Medical regularly reports quarterly and annual financial performance, adjustments to revenue outlook, and steps taken to align operating expenses with its growth priorities.
News flow also includes clinical and scientific updates. AVITA Medical has reported data presentations at medical conferences, including systematic reviews of peer-reviewed literature and real-world registry analyses supporting the RECELL System in acute wound treatment. These items describe outcomes such as reduced donor site burden, faster healing, shorter hospital stays, and favorable economic impact in burn care.
Regulatory and market access developments are another recurring theme. The company has announced CE Mark approval for RECELL GO under the EU Medical Device Regulation, regulatory clearances for RECELL in Europe, Australia, and Japan, and support from Australia’s Medical Services Advisory Committee for the use of autologous skin cell suspension prepared with RECELL in severe burns. Corporate governance updates, such as board appointments and executive transitions, are also disclosed through AVITA Medical’s news releases.
For readers tracking RCEL, this news stream provides insight into the company’s clinical progress, regulatory status, financial performance, and leadership changes, all of which shape its position in the acute wound care and medical device landscape.
AVITA Medical (NASDAQ: RCEL, ASX: AVH), a therapeutic acute wound care company, has announced an upcoming investor webinar briefing scheduled for February 18, 2025, at 2:00 p.m. Pacific Standard Time (February 19, 2025, at 9:00 a.m. Australian Eastern Daylight Time).
The presentation will be led by CEO Jim Corbett and CFO David O'Toole, focusing on the company's financial and business results from their recent fourth quarter and full-year 2024 earnings webcast. The event will include a Q&A session, with participants able to submit questions through the registration page.
Interested shareholders and prospective investors can register for the webinar via a provided Zoom link. A replay of the presentation will be made available on the AVITA Medical investor relations website.
AVITA Medical (NASDAQ: RCEL) reported its Q4 and full-year 2024 financial results. Q4 commercial revenue reached $18.4 million, up 30% year-over-year, with an 87.6% gross profit margin. Full-year 2024 revenue was $64.0 million, increasing 29% from 2023, with an 85.8% gross margin.
Key developments include FDA clearance for Cohealyx™ and RECELL GO® mini in December 2024. The company provided 2025 revenue guidance of $100-106 million, projecting 55-65% growth. AVITA expects to generate free cash flow in H2 2025 and achieve GAAP profitability in Q4 2025.
Q4 net loss was $11.6 million ($0.44 per share), compared to $7.1 million loss in Q4 2023. Full-year 2024 net loss increased to $61.8 million ($2.39 per share). The company ended 2024 with $35.9 million in cash and equivalents.
AVITA Medical (NASDAQ: RCEL) has revised its Q4 2024 commercial revenue expectations to approximately $18.4 million, representing 30% growth year-over-year, down from the previously guided $22.3-24.3 million range. Full-year 2024 revenue is now expected at $64.3 million, up 29% from 2023 but below the earlier guidance of $68-70 million.
The revenue shortfall is primarily attributed to slower purchasing activity, with hospital accounts adjusting year-end inventory levels more significantly than anticipated. The company expects normal purchasing to resume in Q1 2025, including deferred Q4 purchases.
Despite the revision, AVITA Medical maintains a positive outlook, projecting 2025 revenue between $100-106 million, representing 55-65% growth. The company has updated its timeline for achieving cashflow break-even and GAAP profitability to Q4 2025, delayed from Q3 2025. Key growth drivers include the recent launches of PermeaDerm®, RECELL GO™, RECELL GO mini, and Cohealyx™.
AVITA Medical (NASDAQ: RCEL) has received FDA approval for RECELL GO mini, a new disposable cartridge designed for treating smaller wounds up to 480 square centimeters, compared to the standard RECELL GO's 1,920 square centimeters capacity. The device, part of the RECELL GO platform, uses the same multi-use processing device but features a modified cartridge optimized for smaller skin samples, reducing resource use and minimizing waste.
This approval addresses a critical need in the full-thickness skin defect market, particularly targeting high-volume smaller wounds. The company plans to begin rollout in trauma and burn centers during Q1 2025, aiming to provide an entry point for clinicians who may not have previously used the RECELL GO platform for smaller wounds.
AVITA Medical (NASDAQ: RCEL) has received FDA 510(k) clearance for Cohealyx, a collagen-based dermal matrix co-developed with Regenity Biosciences. The product is designed for tissue integration and revascularization in full-thickness wound treatment. Preclinical studies showed Cohealyx generated robust tissue supporting skin grafts faster than leading competitors.
This strategic addition complements AVITA's existing RECELL and PermeaDerm portfolio, expected to triple the company's addressable market in burns. The company plans to initiate clinical studies in early 2025 and launch full commercialization efforts in Q2 2025.
AVITA Medical (NASDAQ: RCEL), a regenerative medicine company specializing in wound care management and skin restoration devices, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. CEO Jim Corbett will deliver a presentation on Thursday, January 16, 2025, at 9:00 a.m. Pacific Time. The presentation will be available via live audio webcast on the company's investor relations website, with a replay option available after the event concludes.
AVITA Medical (NASDAQ: RCEL) has announced its participation in the upcoming Piper Sandler 36th Annual Healthcare Conference. CEO Jim Corbett will deliver a presentation on Tuesday, December 3, 2024, at 11:30 a.m. Eastern Time. The company, which specializes in regenerative medicine and first-in-class devices for wound care management and skin restoration, will provide a live webcast of the fireside chat through their investor relations website. The presentation will remain available for replay after the event concludes.
AVITA Medical (NASDAQ: RCEL) has signed an exclusive distribution agreement with Revolution Surgical Pty to expand into the Australian and New Zealand markets. The agreement covers the distribution of the RECELL® product platform, including RECELL GO® (pending regulatory approval). This strategic partnership represents RECELL's return to Australia, where the technology was originally developed, and aims to enhance product availability and accessibility in these regions.
AVITA Medical (NASDAQ: RCEL) has announced an upcoming investor webinar briefing scheduled for November 12, 2024, at 2:00 p.m. PST. The presentation will be led by CEO Jim Corbett and CFO David O'Toole, covering financial and business results from their recent third-quarter 2024 earnings webcast. The event will include a Q&A session, with participants able to submit questions through the registration page. The webinar will be available for replay on the company's investor relations website after the presentation.
AVITA Medical (NASDAQ: RCEL) reported strong Q3 2024 results with commercial revenue of $19.5 million, up 44% year-over-year. The company achieved a gross profit margin of 83.7%. Key developments include a distribution agreement with Regenity Biosciences for Cohealyx™ and an amended credit agreement with OrbiMed. The company expects Q4 2024 revenue between $22.3-24.3 million and maintains full-year guidance of $68.0-70.0 million. However, net loss widened to $16.2 million ($0.62 per share) compared to $8.7 million ($0.34 per share) in Q3 2023, with operating expenses increasing to $30.2 million.
FAQ
What is the current stock price of Avita Medical (RCEL)?
What is the market cap of Avita Medical (RCEL)?
